Gyre Therapeutics
GYRE
74 hedge funds and large institutions have $135M invested in Gyre Therapeutics in 2013 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 27 increasing their positions, 22 reducing their positions, and 5 closing their positions.
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
23% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 22
18% more capital invested
Capital invested by funds: $114M → $135M (+$20.4M)
4% more funds holding
Funds holding: 71 → 74 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
66% less call options, than puts
Call options by funds: $1.73M | Put options by funds: $5.08M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$10.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.08M |
| 3 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
+$1.03M |
| 4 |
JGC
J. Goldman & Co
New York
|
+$893K |
| 5 |
Franklin Resources
San Mateo,
California
|
+$777K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$21.7M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$599K |
| 3 |
RFC
Russell Frank Company
Seattle,
Washington
|
-$523K |
| 4 |
CCMH
Cornerstone Capital Management Holdings
New York
|
-$422K |
| 5 |
Barclays
London,
United Kingdom
|
-$382K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
76
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$599K | -149 | Closed |
|
|
DTL
77
Dynamic Technology Lab
Singapore
| – | -$167K | -50 | Closed |
|
|
HCM
78
Highbridge Capital Management
New York
| – | -$89K | -27 | Closed |
|
79
Jane Street
New York
| – | -$53K | -16 | Closed |
|
80
BNP Paribas Financial Markets
Paris,
France
| – | -$49.4K | -15 | Closed |
|
GYRE Hedge Fund Activity: Q3 2013 in Review
74 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q3 2013, worth a combined $135M — up 18% from $114M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new GYRE positions and 5 closed out — a net gain of 5 holders — while 27 added to existing stakes and 22 trimmed.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $10.6M. The largest seller was Fidelity Investments, cutting an estimated $21.7M.
- 74 institutional investors held Gyre Therapeutics (GYRE) as of Q3 2013, up from 71 in Q2 2013.
- Funds reported $135M of Gyre Therapeutics stock for Q3 2013, up 18% quarter-over-quarter.
- 10 funds opened new Gyre Therapeutics positions in Q3 2013 and 5 closed out, a net change of +5 holders.
- The largest Gyre Therapeutics buyer in Q3 2013 was Baker Bros. Advisors, an estimated $10.6M added.
- The largest Gyre Therapeutics seller in Q3 2013 was Fidelity Investments, an estimated $21.7M sold.
Based on aggregated 13F filings for Q3 2013.